相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes
Junqing Xie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng et al.
NATURE MEDICINE (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Eric J. Haas et al.
LANCET (2021)
Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England
Annabel A. Powell et al.
EUROSURVEILLANCE (2021)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu et al.
LANCET (2021)
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
Alberto M. Borobia et al.
LANCET (2021)
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
Aziz Sheikh et al.
LANCET (2021)
Heterologous vaccine regimens against COVID-19
Talita Duarte-Salles et al.
LANCET (2021)
Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
Matthias Tenbusch et al.
LANCET INFECTIOUS DISEASES (2021)
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Tina Schmidt et al.
NATURE MEDICINE (2021)
Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study
Carmen Cabezas et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
Xintong Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
David Hillus et al.
LANCET RESPIRATORY MEDICINE (2021)
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Julia W. Gargano et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study
Peter Nordstrom et al.
LANCET REGIONAL HEALTH-EUROPE (2021)
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
Pengfei Jin et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance
Tri-Long Nguyen et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Linking of Primary Care Records to Census Data to Study the Association between Socioeconomic Status and Cancer Incidence in Southern Europe: A Nation-Wide Ecological Study
Maria Garcia-Gil et al.
PLOS ONE (2014)
Construcción de un índice de privación a partir de datos censales en grandes ciudades españolas (Proyecto MEDEA)
M. Felícitas Domínguez-Berjón et al.
Gaceta Sanitaria (2008)